APA (7th ed.) Citation

Su, C., Chen, M., Chen, L., Ho, Y., Ho, H., Lin, S., . . . Sheu, M. (2018). Bispecific antibodies (anti-mPEG/anti-HER2) for active tumor targeting of docetaxel (DTX)-loaded mPEGylated nanocarriers to enhance the chemotherapeutic efficacy of HER2-overexpressing tumors. Drug delivery, 25(1), 1066-1079. https://doi.org/10.1080/10717544.2018.1466936

Chicago Style (17th ed.) Citation

Su, Chia-Yu, Michael Chen, Ling-Chun Chen, Yuan-Soon Ho, Hsiu-O Ho, Shyr-Yi Lin, Kuo-Hsiang Chuang, and Ming-Thau Sheu. "Bispecific Antibodies (anti-mPEG/anti-HER2) for Active Tumor Targeting of Docetaxel (DTX)-loaded MPEGylated Nanocarriers to Enhance the Chemotherapeutic Efficacy of HER2-overexpressing Tumors." Drug Delivery 25, no. 1 (2018): 1066-1079. https://doi.org/10.1080/10717544.2018.1466936.

MLA (9th ed.) Citation

Su, Chia-Yu, et al. "Bispecific Antibodies (anti-mPEG/anti-HER2) for Active Tumor Targeting of Docetaxel (DTX)-loaded MPEGylated Nanocarriers to Enhance the Chemotherapeutic Efficacy of HER2-overexpressing Tumors." Drug Delivery, vol. 25, no. 1, 2018, pp. 1066-1079, https://doi.org/10.1080/10717544.2018.1466936.